BioWorld

April 25, 2005

Lifted By Higher Product Sales, Amgen Beats Consensus EPS

Beating Wall Street estimates, Amgen Inc. performed well in the first quarter, reporting strong revenue for most of its products, despite Medicare reimbursement changes. (BioWorld Today) Read More

Solexa Signs Deal To Raise $32.5M, Advance Platform

Novel Approach To Synthesis Causing Tetracycline Variety

Recent Stem Cell Bill Forbids Human Reproductive Cloning

Hamilton Pharmaceuticals' First Financing: $11M For CNS Drugs

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for April 24, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for April 21, 2026

A free gene therapy? Regeneron’s Otarmeni approved for hearing loss

BioWorld

Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...

Psychedelic space expanding on Trump’s EO

BioWorld

Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...

At AACR: Epigenetic fingerprints in metastases track tumor origin

BioWorld

When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...